Nuvectis Pharma, Inc. (NVCT)
| Market Cap | 253.32M -8.6% |
| Revenue (ttm) | n/a |
| Net Income | -29.59M |
| EPS | -1.30 |
| Shares Out | 26.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,835 |
| Open | 9.61 |
| Previous Close | 9.75 |
| Day's Range | 9.47 - 9.72 |
| 52-Week Range | 5.55 - 13.34 |
| Beta | -0.07 |
| Analysts | Strong Buy |
| Price Target | 16.80 (+75.92%) |
| Earnings Date | May 5, 2026 |
About NVCT
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is base... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for NVCT stock is "Strong Buy." The 12-month stock price target is $16.8, which is an increase of 75.92% from the latest price.
News
Nuvectis Pharma Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
NXP900, a highly selective SRC inhibitor, shows strong safety and potency in early trials, achieving up to 95% SRC inhibition and avoiding major side effects. Ongoing Phase I-B trials target enriched patient populations and include combinations with leading lung cancer therapies, addressing a large market with substantial unmet need.
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative p...
Nuvectis Pharma Slides: Corporate presentation
Nuvectis Pharma has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
Nuvectis Pharma Earnings release: Q1 2026
Nuvectis Pharma released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Nuvectis Pharma Quarterly report: Q1 2026
Nuvectis Pharma has published its Q1 2026 quarterly earnings report on May 5, 2026.
Nuvectis Pharma Proxy statement: Proxy filing
Nuvectis Pharma filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Nuvectis Pharma Proxy statement: Proxy filing
Nuvectis Pharma filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
Fort Lee, NJ, March 31, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
Nuvectis Pharma management to meet with Maxim
Meeting to be held on March 25 hosted by Maxim.
Nuvectis Pharma Slides: Corporate presentation
Nuvectis Pharma has posted slides in relation to its latest quarterly earnings report, which was published on March 13, 2026.
Nuvectis Pharma files $150M mixed securities shelf
16:03 EST Nuvectis Pharma (NVCT) files $150M mixed securities shelf
Nuvectis Pharma Registration statement: Registration Filing
Nuvectis Pharma filed a registration statement on February 13, 2026, providing details about a securities offering with the SEC.
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovativ...
Nuvectis Pharma Earnings release: Q4 2025
Nuvectis Pharma released its Q4 2025 earnings on February 11, 2026, summarizing the period's financial results.
Nuvectis Pharma Annual report: Q4 2025
Nuvectis Pharma has published its Q4 2025 annual report on February 11, 2026.
Nuvectis Pharma announces initiation of Phase 1b study of NXP900
Nuvectis Pharma (NVCT) announced the initiation of the Phase 1b study of NXP900 in combination with osimertinib in patients with EGFRmut+ NSCLC. NXP900, an oral small molecule drug candidate, is…
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
The study is designed to evaluate the safety and clinical activity of NXP900 in combination with osimertinib in patients with epidermal growth factor receptor mutated (EGFR mut+) non-small cell lung c...
Nuvectis Pharma Transcript: KOL Event
NXP900, a novel oral Src inhibitor, is advancing in a broad phase 1b program targeting major unmet needs in advanced solid tumors, especially non-small cell lung cancer. Early data show high Src inhibition and favorable tolerability, with multiple combination studies and data readouts expected in 2026.
Nuvectis Pharma Slides: KOL Event
Nuvectis Pharma has posted slides in relation to its latest quarterly earnings report, which was published on December 2, 2025.
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
Fort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT, the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medic...
Nuvectis Pharma Earnings release: Q3 2025
Nuvectis Pharma released its Q3 2025 earnings on November 4, 2025, summarizing the period's financial results.
Nuvectis Pharma Quarterly report: Q3 2025
Nuvectis Pharma has published its Q3 2025 quarterly earnings report on November 4, 2025.
Nuvectis Pharma reports Q3 EPS (44c), consensus (25c)
Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “Our activity in the third quarter focused on advancing the clinical work required to support our ambitious Phase 1b program…
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ: NVCT), the tables were not included. The...